NEW YORK, Oct 7, 2016 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced it will make a keynote presentation on its nucleic acid polymer (NAP) technology during the 3rd World Conference of Hepatitis and Liver Diseases to be held October 10-12, 2016 in Dubai, UAE.
Replicor’s invited keynote presentation will provide a comprehensive overview of the broad spectrum antiviral activity of NAPs and their unparalleled antiviral effects clinically against chronic HBV infection.
Replicor was also invited to give a second presentation focusing on the specific application of NAPs for treating HBV / HDV co-infection.
The Middle East is a region of the world with a substantial burden of HBV infection and HBV / HDV co-infection. These presentations will showcase Replicor’s clinical data demonstrating the unique ability of NAP-based combination therapy to eliminate serum HBsAg and to achieve functional cure in patients with HBV and HBV / HDV co-infection.
For further information about the Hepatitis 2016 Meeting visit: http://hepatitis.omicsgroup.com.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.